Archive | AYA RSS for this section

3CTN Supporting Development of a ALL trial in the AYA Population

Adolescents and Young Adults (AYA) diagnosed with cancer have a unique set of challenges throughout their cancer journey and historically there have been limited formal clinical trials available to this population. To help support research in this important yet underserved segment of the Canadian cancer population, 3CTN is facilitating the development of a new clinical trial for the AYA population. The process began in the spring of 2015 with the release of a request for applications, which asked AYA researchers to submit clinical trial proposals.

Over the past few months, through a formal review and selection process, one project proposal for a trial in Acute Lymphoblastic Leukemia (ALL) was ultimately selected. On November 30 2015, 3CTN and our collaborators* held a workshop in Montreal, Quebec focused on developing this proposed pan-Canadian clinical trial. The workshop brought together principal investigators and site research staff from many Canadian pediatric and adult cancer centres with the common goal of launching a trial to address current knowledge gaps in AYA ALL therapy. Topics covered at the workshop included prioritizing the clinical needs of AYA ALL patients, identification of potential new agents and the status of the relevant diagnostic tests that will be required for a trial. A smaller working group will now focus on designing a draft protocol for a study to open within the next year. Clinical trials targeted to AYA with ALL will ultimately improve the standard of care and health outcomes for this population.

After the workshop, 3CTN provided a satisfaction survey and invited participants to provide feedback on the workshop. Nearly 70 per cent of attendees responded to the survey and indicated that overall, they were pleased with the workshop and that it met its stated goals and objectives.

The final goal of this AYA ALL trial development process will be a clinical trial in which Network centres can participate via the 3CTN Portfolio. Collectively our Network’s involvement may help decrease the knowledge gap in therapy for AYA Canadians diagnosed with ALL.

AYA-specific indicators for cancer system performance measurement — Volunteers Required

The Canadian Task Force on Adolescents and Young Adults (AYA) with Cancer is looking for individuals who would be interested in being part of a team which will carry out the development of AYA cancer system performance measurement capacity.  The work will begin with refinement of a list of indicators, and end with the production of a CPAC Spotlight Report in March 2017 describing the indicator development work and plans for their incorporation within CPAC’s established system performance measurement and reporting.


Since 2008 the Task Force has been dedicated to addressing the priority challenges in AYA cancer. The Task Force is funded by the Canadian Partnership Against Cancer (CPAC), and is co-chaired by Drs. Paul Rogers, Ronnie Barr, and Brent Schacter.

The Task Force recently received further funding to develop AYA-specific indicators for cancer system performance measurement. AYA-specific metrics are required to address issues unique to AYA with cancer, related to their age and developmental stage. AYA-specific metrics will be an important addition to CPAC’s body of indicators and its system performance reporting. These metrics will identify opportunities to improve quality of care and identify benchmarks to achieve short-term, medium-term and long-term outcome-improvement goals.  AYA-specific system performance information will form the core of the case to be made for action, allocation and re-allocations within the health system.

The AYA Task Force would greatly appreciate any volunteers, or information on other individuals who may be interested in this project. Please do not hesitate to contact the AYA Task Force, or any of the co-chairs.  Contact information for the AYA Task Force can be found at:

AYA Task Force News Flash

The Summer edition of the AYA Task Force News Flash can be found here.

INVITATION: C17 AGM Reception and Round Table Discussions

All C17 Directors, Co-Chairs, Committee Members, Funders, Parent/Patient representatives and local health professionals are encouraged to attend. Discussions will focus on research, funding and advocacy priorities for C17

One of our key goals is to identify and discuss the priorities and opportunities that C17 is addressing. Some of these include:

  • Adolescent and Young Adult Cancer – the work of our C17 Task Force, the partnership with NCIC CTG to develop an AYA Platform, the 3CTN RFA for AYA clinical trials, and the potential to increase clinical trials enrollment under 3CTN.
  • 3CTN – how do we meet our goals to increase clinical trial enrollment and trigger funding from 3CTN?
  • Research funding – we are exploring new partnered funding for research, including Cancer Research Society, Terry Fox Research Institute, and 3CTN.
  • Funding and Partnerships – our primary funder is Childhood Cancer Canada Foundation, and we have relationships with several other foundations and parent groups. How can we bring them all to the table and meet everyone’s goals?
  • Advocacy – what factors are influencing research and education in Canada today and how can we address them.

We would like to encourage all committees, directors and C17 members to participate in an interactive dialogue during this Wednesday evening session. Our goal is to create some dialogue between funders, parents and health professionals about our priorities.

Please register (no cost) at

Wednesday, June 3

6:00 – 8:30 PM  (A light dinner will be served)

2nd Floor Gallery, PGCRL, the Hospital for Sick Children

Webinar: Access to NCTN AYA Trials, April 22

The CTSU is planning a webinar entitled, “Access to NCTN AYA Trials”, to highlight the need for sites to activate and offer cancer clinical trials to Adolescents and Young Adults (AYA). This webinar is set for Wednesday, April 22nd, 2015 at 4pm – 5pm EST.

NCI’s Dr. Nita Seibel will provide an overview on the NCTN AYA trials available on the CTSU, followed by a detailed summary of the COG-NRG ARST 1321 trial, (Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib), given by Study Co-Chair, Dr. Aaron Weiss from COG.

The agenda also will include:

  • Suggestions from a few NCTN sites on how they’ve successfully opened AYA trials for both pediatric and adult patients.
  • Information provided by NCI’s CIRB on their review processes for these trials and activation at sites treating pediatric or older adult patients.
  • A brief recap by CTSU on site crediting for AYA trials.

The webinar will end with a Q&A session for you to ask questions from any of the webinar presenters about the trial and any issues regarding activating and accruing to AYA trials.

This webinar kicks off a new series of webinars by the CTSU. The goal of these webinars is to address key concerns that affect accrual to NCI-supported trials, and raise of awareness of trials among NCTN sites. The series is available to all sites and individuals interested in attending.

To attend the webinar on the NCTN AYA trials, simply go to the link below, and click register.

AYA Concept Project Proposals – Request for Submissions Due April 24

3CTN in collaboration with C17 and NCIC CTG is requesting submissions for Adolescent and Young Adult (AYA) Clinical Research Concept Projects to be discussed and further developed at a 3CTN funded AYA workshop in the fall of 2015. The goal will be to develop a clinical trial(s) or clinical research study(ies) that address(es) key gaps or priority areas of AYA-focused cancer treatments. 3CTN will provide funding for the workshop including travel expenses. Clinical trials should be eligible for the 3CTN portfolio; however, projects will require funding from other sources.

Guidelines and forms can be downloaded below, and can be found on the 3CTN website.

Deadline for submission to is April 24th, 5pm EST.